Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00480194 |
Recruitment Status :
Completed
First Posted : May 30, 2007
Last Update Posted : May 7, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Common Cold | Drug: xylometazoline hydrochloride and ipratropium bromide (ZyComb) |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting |
Study Start Date : | December 2006 |
Actual Primary Completion Date : | January 2008 |
Actual Study Completion Date : | January 2008 |
- Drug: xylometazoline hydrochloride and ipratropium bromide (ZyComb)
Common cold in a real-life OTC setting

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- For inclusion the patient must buy ZyComb® nasal spray with the intention to start using it either the same or the next day.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00480194
Study Chair: | Nycomed Clinical Trial Operations | Headquaters |
Responsible Party: | Nycomed |
ClinicalTrials.gov Identifier: | NCT00480194 |
Other Study ID Numbers: |
XY-005-IM |
First Posted: | May 30, 2007 Key Record Dates |
Last Update Posted: | May 7, 2012 |
Last Verified: | February 2008 |
Common Cold Respiratory Tract Infections Infections Picornaviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Diseases Xylometazoline Bromides Ipratropium Anticonvulsants Bronchodilator Agents |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Nasal Decongestants Vasoconstrictor Agents |